2164 Circulation June 4, 2013 of predicted cTTR, 8 the benefit of apixaban was greatest at
centers with the lowest predicted TTR. However, the rate of major bleeding appeared to be …

Background—In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and …

Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

It remains unknown whether the comparative effectiveness of direct oral anticoagulants
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …

Background Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may
have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. Methods …

The effectiveness and safety of apixaban for stroke prevention in atrial fibrillation (SPAF)
demonstrated in ARISTOTLE needs to be confirmed in daily care. To evaluate effectiveness …

Background Recent reports suggest an important contribution from frequent off-label use of
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …

Atrial fibrillation is a common, costly and morbid cardiovascular arrhythmia. Stroke
prevention remains the mainstay of treatment for atrial fibrillation, and the recent advent of …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …